Puma Biotechnology | PBYI - Loan Capital


Puma Biotechnology reported $10.87M in Loan Capital for its fiscal quarter ending in June of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Incyte USD 29.41M 785K Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Moderna USD 603M 7M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Takeda JPY 4.37T 99.51B Mar/2026
TG Therapeutics USD 745.14M 499.5M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025